 |
|
|
|
Ambler class |
Protein name |
PDB code |
Resolution (Å) |
Release date |
UniProt code |
PubMed ID |
DOI |
PDB |
Mutations |
Ligands |
Space group |
Unit cell parameters |
Z value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ||||||||
| A | BEL-1 | 4MX4 | 1.60 | 2014-10-01 | Q3SAW3 | pdb | CL EDO FLC IPA PGE | P 21 21 2 | 100.270 120.920 53.410 ♦ 90.00 90.00 90.00 | 8 | |||
| A | BEL-1 | 4MXB | 1.79 | 2014-10-01 | Q3SAW3 | pdb | *IM2 CL | P 1 21 1 | 53.980 95.860 103.420 ♦ 90.00 91.97 90.00 | 8 | |||
| A | BEL-1 | 4MXG | 1.48 | 2014-10-01 | Q3SAW3 | pdb | CL FLC MPD | P 1 21 1 | 54.840 94.690 103.680 ♦ 90.00 92.64 90.00 | 8 | |||
| A | BEL-1 | 4MXH | 1.85 | 2014-10-15 | Q3SAW3 | pdb | *3P7 *MOX CL | P 21 21 21 | 70.530 80.910 86.640 ♦ 90.00 90.00 90.00 | 8 | |||
| A | BEL-1 | 5EOE | 1.60 | 2016-09-21 | Q3SAW3 | 27671060 | 10.1128/AAC.00936-16 | pdb | 1PE CIT CL EDO IPA MRD PGE | P 21 21 2 | 100.270 120.920 53.410 ♦ 90.00 90.00 90.00 | 8 | |
| A | BEL-1 | 5EOO | 1.48 | 2016-09-21 | Q3SAW3 | 27671060 | 10.1128/AAC.00936-16 | pdb | CIT CL IPA MRD PGE | P 1 21 1 | 54.840 94.690 103.680 ♦ 90.00 92.64 90.00 | 8 | |
| A | BEL-1 | 5EPH | 1.79 | 2016-09-21 | Q3SAW3 | 27671060 | 10.1128/AAC.00936-16 | pdb | *ID1 CL MRD | P 1 21 1 | 53.980 95.860 103.420 ♦ 90.00 91.97 90.00 | 8 | |
| A | BEL-1 | 5EUA | 1.85 | 2016-09-21 | Q3SAW3 | 27671060 | 10.1128/AAC.00936-16 | pdb | *3P7 NA | P 21 21 21 | 70.530 80.910 86.640 ♦ 90.00 90.00 90.00 | 8 |
Statistics (number of structures): Overall (1663); class A (626); subclass B1 (403); subclass B2 (16); subclass B3 (104); class C (246); class D (268).
Last updated: November 20, 2024.
If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.
The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).
Contact: contact@bldb.eu